JP5608681B2 - 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質 - Google Patents

活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質 Download PDF

Info

Publication number
JP5608681B2
JP5608681B2 JP2011543800A JP2011543800A JP5608681B2 JP 5608681 B2 JP5608681 B2 JP 5608681B2 JP 2011543800 A JP2011543800 A JP 2011543800A JP 2011543800 A JP2011543800 A JP 2011543800A JP 5608681 B2 JP5608681 B2 JP 5608681B2
Authority
JP
Japan
Prior art keywords
particulate material
active ingredient
coating
binder
carbonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011543800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508786A (ja
JP2012508786A5 (cg-RX-API-DMAC7.html
Inventor
ルボン、クリストフ
スュプリ、パスカル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debregeas Et Associes Pharma SAS
Original Assignee
Debregeas Et Associes Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40348849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5608681(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma SAS filed Critical Debregeas Et Associes Pharma SAS
Publication of JP2012508786A publication Critical patent/JP2012508786A/ja
Publication of JP2012508786A5 publication Critical patent/JP2012508786A5/ja
Application granted granted Critical
Publication of JP5608681B2 publication Critical patent/JP5608681B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fertilizers (AREA)
  • Glanulating (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011543800A 2008-11-14 2009-11-13 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質 Expired - Fee Related JP5608681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0857764A FR2938432B1 (fr) 2008-11-14 2008-11-14 Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
FR0857764 2008-11-14
PCT/FR2009/052180 WO2010055268A1 (fr) 2008-11-14 2009-11-13 Nouveau procédé de préparation de granulés de principes actifs, et granulés tels qu'obtenus

Publications (3)

Publication Number Publication Date
JP2012508786A JP2012508786A (ja) 2012-04-12
JP2012508786A5 JP2012508786A5 (cg-RX-API-DMAC7.html) 2014-05-22
JP5608681B2 true JP5608681B2 (ja) 2014-10-15

Family

ID=40348849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543800A Expired - Fee Related JP5608681B2 (ja) 2008-11-14 2009-11-13 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質

Country Status (25)

Country Link
US (1) US20110280945A1 (cg-RX-API-DMAC7.html)
EP (1) EP2349226A1 (cg-RX-API-DMAC7.html)
JP (1) JP5608681B2 (cg-RX-API-DMAC7.html)
KR (1) KR101585705B1 (cg-RX-API-DMAC7.html)
CN (1) CN102223879A (cg-RX-API-DMAC7.html)
AR (1) AR074330A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009315449B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916019A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743753A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001115A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382108A2 (cg-RX-API-DMAC7.html)
CU (1) CU20110107A7 (cg-RX-API-DMAC7.html)
EA (1) EA201100757A1 (cg-RX-API-DMAC7.html)
FR (1) FR2938432B1 (cg-RX-API-DMAC7.html)
IL (1) IL212850A0 (cg-RX-API-DMAC7.html)
MA (1) MA32789B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005072A (cg-RX-API-DMAC7.html)
NZ (1) NZ592857A (cg-RX-API-DMAC7.html)
PE (1) PE20110945A1 (cg-RX-API-DMAC7.html)
SG (1) SG195651A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000235A1 (cg-RX-API-DMAC7.html)
TW (1) TWI522113B (cg-RX-API-DMAC7.html)
UA (1) UA103781C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010055268A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103543B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US9241956B2 (en) * 2012-11-05 2016-01-26 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US11058635B1 (en) * 2020-10-15 2021-07-13 King Abdulaziz University Oral administration of 5-FU in a gelling nanosuspension for targeted delivery to treat colorectal cancers
KR20240157168A (ko) * 2023-04-24 2024-11-01 주식회사 케이티앤지 바인더를 사용하는 파우치 충진 물질의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
JP2820829B2 (ja) * 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
JP2002544220A (ja) * 1999-05-17 2002-12-24 デー.ベー.エフ. 植物物質を含有する顆粒及びその製造方法
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US9247765B2 (en) * 2004-01-14 2016-02-02 Omniactive Health Technologies Limited Stable beadlets of lipophilic nutrients
FR2880541B1 (fr) * 2005-01-10 2008-02-22 Amalric Veret Une nouvelle formule de plantes sous forme de micro-granules de xilitol pour renforcer les effets des plantes et leurs proprietes par une meilleure assimilation
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
ES2403103T3 (es) * 2007-02-14 2013-05-14 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Agente dispersante para pigmento orgánico y su utilización
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system

Also Published As

Publication number Publication date
ZA201103543B (en) 2012-01-25
US20110280945A1 (en) 2011-11-17
EA201100757A1 (ru) 2011-12-30
FR2938432A1 (fr) 2010-05-21
CU20110107A7 (es) 2012-01-31
CN102223879A (zh) 2011-10-19
CO6382108A2 (es) 2012-02-15
JP2012508786A (ja) 2012-04-12
EP2349226A1 (fr) 2011-08-03
AU2009315449B2 (en) 2015-03-26
NZ592857A (en) 2013-07-26
MA32789B1 (fr) 2011-11-01
UA103781C2 (uk) 2013-11-25
TWI522113B (zh) 2016-02-21
SG195651A1 (en) 2013-12-30
KR20110095888A (ko) 2011-08-25
PE20110945A1 (es) 2012-02-01
AR074330A1 (es) 2011-01-05
CA2743753A1 (fr) 2010-05-20
AU2009315449A1 (en) 2010-05-20
CL2011001115A1 (es) 2011-11-11
WO2010055268A1 (fr) 2010-05-20
IL212850A0 (en) 2011-07-31
BRPI0916019A2 (pt) 2015-11-10
KR101585705B1 (ko) 2016-01-15
TW201029667A (en) 2010-08-16
FR2938432B1 (fr) 2011-05-20
MX2011005072A (es) 2011-10-03
TN2011000235A1 (fr) 2012-12-17

Similar Documents

Publication Publication Date Title
JP2012508784A (ja) γ−ヒドロキシ酪酸に基づく新規の組成物
JP7398999B2 (ja) 薬物動態が改善された放出調節ガンマ-ヒドロキシ酪酸塩製剤
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
JP4789806B2 (ja) パントプラゾール多粒子処方
JP7850207B2 (ja) 医薬品の崩壊時間を安定させるための、保管中の薬物粒子コーティング材料の凝集を最小限に抑える
JP2002523443A (ja) オメプラゾール製剤
CN101951767A (zh) 包含苯海拉明的口服崩解片剂
JP5160423B2 (ja) 水易溶性薬物含有球状素顆粒の製造方法
JP3693270B2 (ja) フィルムコーティング顆粒およびその製造方法
JP4234427B2 (ja) 活性成分をベースとする微小顆粒およびその製造方法
MX2010011409A (es) Forma oral solida con perfil de liberacion dual que contiene particulas multiples.
JP4447166B2 (ja) 硫酸モルヒネマイクロ顆粒剤、製法および医薬調製物
JP3645816B2 (ja) ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物
JP2012508786A (ja) 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質
CN1713896B (zh) 球形体、其制备方法以及药物组合物
WO2003070223A1 (en) Sustained release preparations and process for producing the same
EP4265242B1 (en) High dose tranexamic acid composition and process for preparation thereof
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
EP2808019B1 (en) Improved nitazoxanide composition and preparation method thereof
JP3343144B2 (ja) マイクロカプセル
JP2541835B2 (ja) 持続放出型薬理組成物の製法およびこれにより得られる組成物
WO2005016317A1 (en) Process for manufacture of extended release pellets containing diltiazem hci

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140317

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140901

R150 Certificate of patent or registration of utility model

Ref document number: 5608681

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees